文献速递类风湿关节炎其他结缔组织病

系统性自身免疫性风湿病患者中COVID-19症状持续时间延长的研究:来自COVID-19全球风湿病联盟疫苗调查的结果

Prolonged COVID-19 symptom duration in people with systemic autoimmune rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey.
PubMed 文献 · RMD Open · 2022-01-01

基于COVID-19全球风湿病联盟疫苗调查(2021年4月2日至10月15日)数据,纳入441例报告实验室确诊COVID-19的系统性自身免疫性风湿病患者,分析症状持续≥28天的比例及相关因素。结果显示24.2%的患者症状持续≥28天,9.8%持续≥90天;住院治疗、合并症数量及骨关节炎与症状延长风险升高相关,2021年发病者风险较低。

要点

  • 441例系统性自身免疫性风湿病患者中,24.2%报告COVID-19症状持续≥28天,9.8%持续≥90天。
  • 因COVID-19住院且急性症状轻微者,症状持续≥28天的比值比为6.49(95%CI 3.03至14.1)。
  • 合并症数量每增加1种,症状持续≥28天的比值比为1.11(95%CI 1.02至1.21)。

核心结论

  • 大多数系统性自身免疫性风湿病患者在COVID-19发病后第15天症状完全缓解,但约四分之一症状持续≥28天,约十分之一持续≥90天。
  • 未来需研究免疫调节药物、系统性自身免疫性风湿病类型/复发、疫苗剂次及新型病毒变异株与COVID-19症状延长及其他急性期后遗症的可能关系。

研究设计与样本

  • 分析COVID-19全球风湿病联盟疫苗调查(2021年4月2日至2021年10月15日)数据,识别报告实验室确诊COVID-19的系统性自身免疫性风湿病患者。
  • 共纳入441例 respondent,平均年龄48.2岁,女性占83.7%,类风湿关节炎占39.5%。
  • 采用logistic回归分析基线特征与症状持续≥28天的关联。

主要发现

  • COVID-19症状持续时间中位数为15天(IQR 7至25天)。
  • 107例(24.2%)症状持续≥28天;42/429例(9.8%)报告症状持续≥90天。
  • 因COVID-19住院且急性症状轻微者相比未住院且急性症状轻微者,症状持续≥28天的年龄校正OR为6.49(95%CI 3.03至14.1)。
  • 合并症数量每增加1种,症状持续≥28天的年龄校正OR为1.11(95%CI 1.02至1.21)。
  • 骨关节炎患者症状持续≥28天的年龄校正OR为2.11(95%CI 1.01至4.27);2021年发病相比2020年6月或更早发病,年龄校正OR为0.42(95%CI 0.21至0.81)。

关键数值与推荐

  • 症状持续时间延长定义为持续28天或更长。
  • 症状持续≥28天者107/441例(24.2%);症状持续≥90天者42/429例(9.8%)。
  • 住院且急性症状轻微者 vs 未住院且急性症状轻微者:年龄校正OR 6.49(95%CI 3.03至14.1)。
  • 合并症数量:每增加1种,年龄校正OR 1.11(95%CI 1.02至1.21)。
  • 骨关节炎:年龄校正OR 2.11(95%CI 1.01至4.27);2021年发病 vs 2020年6月或更早:年龄校正OR 0.42(95%CI 0.21至0.81)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We investigated prolonged COVID-19 symptom duration, defined as lasting 28 days or longer, among people with systemic autoimmune rheumatic diseases (SARDs). METHODS: We analysed data from the COVID-19 Global Rheumatology Alliance Vaccine Survey (2 April 2021-15 October 2021) to identify people with SARDs reporting test-confirmed COVID-19. Participants reported COVID-19 severity and symptom duration, sociodemographics and clinical characteristics. We reported the proportion experiencing prolonged symptom duration and investigated associations with baseline characteristics using logistic regression. RESULTS: We identified 441 respondents with SARDs and COVID-19 (mean age 48.2 years, 83.7% female, 39.5% rheumatoid arthritis). The median COVID-19 symptom duration was 15 days (IQR 7, 25). Overall, 107 (24.2%) respondents had prolonged symptom duration (≥28 days); 42/429 (9.8%) reported symptoms lasting ≥90 days. Factors associated with higher odds of prolonged symptom duration included: hospitalisation for COVID-19 vs not hospitalised and mild acute symptoms (age-adjusted OR (aOR) 6.49, 95% CI 3.03 to 14.1), comorbidity count (aOR 1.11 per comorbidity, 95% CI 1.02 to 1.21) and osteoarthritis (aOR 2.11, 95% CI 1.01 to 4.27). COVID-19 onset in 2021 vs June 2020 or earlier was associated with lower odds of prolonged symptom duration (aOR 0.42, 95% CI 0.21 to 0.81). CONCLUSION: Most people with SARDs had complete symptom resolution by day 15 after COVID-19 onset. However, about 1 in 4 experienced COVID-19 symptom duration 28 days or longer; 1 in 10 experienced symptoms 90 days or longer. Future studies are needed to investigate the possible relationships between immunomodulating medications, SARD type/flare, vaccine doses and novel viral variants with prolonged COVID-19 symptoms and other postacute sequelae of COVID-19 among people with SARDs.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. DiIorio M, Kennedy K, Liew JW, et al. Prolonged COVID-19 symptom duration in people with systemic autoimmune rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. RMD Open. 2022. PMID: 36104117. doi:10.1136/rmdopen-2022-002587

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。